{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T03:13:19Z","timestamp":1767237199480,"version":"3.40.3"},"publisher-location":"New York, NY","reference-count":20,"publisher":"Springer US","isbn-type":[{"type":"print","value":"9781071625644"},{"type":"electronic","value":"9781071625651"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1007\/978-1-0716-2565-1_25","type":"book-chapter","created":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T21:02:45Z","timestamp":1663707765000},"page":"271-284","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Plasma Lysosphingolipid Biomarker Measurement by Liquid Chromatography Tandem Mass Spectrometry"],"prefix":"10.1007","author":[{"given":"Brandon B.","family":"Stauffer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunli","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,21]]},"reference":[{"key":"25_CR1","doi-asserted-by":"publisher","first-page":"6387","DOI":"10.1021\/cr2002917","volume":"111","author":"AH Merrill","year":"2011","unstructured":"Merrill AH (2011) Sphingolipid and glycosphingolipid metabolic pathways in the era of Sphingolipidomics. Chem Rev 111:6387\u20136422. https:\/\/doi.org\/10.1021\/cr2002917","journal-title":"Chem Rev"},{"key":"25_CR2","doi-asserted-by":"publisher","first-page":"6881","DOI":"10.3390\/ijms21186881","volume":"21","author":"AE Ryckman","year":"2020","unstructured":"Ryckman AE, Brockhausen I, Walia JS (2020) Metabolism of glycosphingolipids and their role in the pathophysiology of lysosomal storage disorders. IJMS 21:6881. https:\/\/doi.org\/10.3390\/ijms21186881","journal-title":"IJMS"},{"key":"25_CR3","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/j.1471-4159.1982.tb07950.x","volume":"39","author":"O Nilsson","year":"1982","unstructured":"Nilsson O, Svennerholm L (1982) Accumulation of glucosylceramide and Glucosylsphingosine (Psychosine) in cerebrum and cerebellum in infantile and juvenile Gaucher disease. J Neurochem 39:709\u2013718. https:\/\/doi.org\/10.1111\/j.1471-4159.1982.tb07950.x","journal-title":"J Neurochem"},{"key":"25_CR4","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S1096-7192(02)00117-8","volume":"76","author":"E Orvisky","year":"2002","unstructured":"Orvisky E, Park JK, LaMarca ME et al (2002) Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype. Mol Genet Metab 76:262\u2013270. https:\/\/doi.org\/10.1016\/S1096-7192(02)00117-8","journal-title":"Mol Genet Metab"},{"key":"25_CR5","doi-asserted-by":"publisher","first-page":"e118","DOI":"10.1182\/blood-2011-05-352971","volume":"118","author":"N Dekker","year":"2011","unstructured":"Dekker N, van Dussen L, Hollak CEM et al (2011) Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. Blood 118:e118\u2013e127. https:\/\/doi.org\/10.1182\/blood-2011-05-352971","journal-title":"Blood"},{"key":"25_CR6","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1002\/ajh.24877","volume":"92","author":"PK Mistry","year":"2017","unstructured":"Mistry PK, Lukina E, Ben Turkia H et al (2017) Outcomes after 18 months of eliglustat therapy in treatment-na\u00efve adults with Gaucher disease type 1: the phase 3 ENGAGE trial. Am J Hematol 92:1170\u20131176. https:\/\/doi.org\/10.1002\/ajh.24877","journal-title":"Am J Hematol"},{"key":"25_CR7","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ymgme.2017.08.005","volume":"122","author":"D Elstein","year":"2017","unstructured":"Elstein D, Mellgard B, Dinh Q et al (2017) Reductions in glucosylsphingosine (lyso-Gb1) in treatment-na\u00efve and previously treated patients receiving velaglucerase alfa for type 1 Gaucher disease: data from phase 3 clinical trials. Mol Genet Metab 122:113\u2013120. https:\/\/doi.org\/10.1016\/j.ymgme.2017.08.005","journal-title":"Mol Genet Metab"},{"key":"25_CR8","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0022-2275(20)39839-4","volume":"21","author":"L Svennerholm","year":"1980","unstructured":"Svennerholm L, Vanier MT, M\u00e5nsson JE (1980) Krabbe disease: a galactosylsphingosine (psychosine) lipidosis. J Lipid Res 21:53\u201364. https:\/\/doi.org\/10.1016\/S0022-2275(20)39839-4","journal-title":"J Lipid Res"},{"key":"25_CR9","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1007\/s10545-015-9822-z","volume":"38","author":"CT Turgeon","year":"2015","unstructured":"Turgeon CT, Orsini JJ, Sanders KA et al (2015) Measurement of psychosine in dried blood spots \u2014 a possible improvement to newborn screening programs for Krabbe disease. J Inherit Metab Dis 38:923\u2013929. https:\/\/doi.org\/10.1007\/s10545-015-9822-z","journal-title":"J Inherit Metab Dis"},{"key":"25_CR10","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.ymgme.2017.05.015","volume":"121","author":"ML Escolar","year":"2017","unstructured":"Escolar ML, Kiely BT, Shawgo E et al (2017) Psychosine, a marker of Krabbe phenotype and treatment effect. Mol Genet Metab 121:271\u2013278. https:\/\/doi.org\/10.1016\/j.ymgme.2017.05.015","journal-title":"Mol Genet Metab"},{"key":"25_CR11","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1038\/s41436-020-0764-y","volume":"22","author":"AJ Guenzel","year":"2020","unstructured":"Guenzel AJ, Turgeon CT, Nickander KK et al (2020) The critical role of psychosine in screening, diagnosis, and monitoring of Krabbe disease. Genet Med 22:1108\u20131118. https:\/\/doi.org\/10.1038\/s41436-020-0764-y","journal-title":"Genet Med"},{"key":"25_CR12","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ymgme.2010.03.020","volume":"100","author":"T Togawa","year":"2010","unstructured":"Togawa T, Kodama T, Suzuki T et al (2010) Plasma globotriaosylsphingosine as a biomarker of Fabry disease. Mol Genet Metab 100:257\u2013261. https:\/\/doi.org\/10.1016\/j.ymgme.2010.03.020","journal-title":"Mol Genet Metab"},{"key":"25_CR13","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.ymgme.2017.06.006","volume":"121","author":"A Nowak","year":"2017","unstructured":"Nowak A, Mechtler T, Kasper DC, Desnick RJ (2017) Correlation of Lyso-Gb3 levels in dried blood spots and sera from patients with classic and later-onset Fabry disease. Mol Genet Metab 121:320\u2013324. https:\/\/doi.org\/10.1016\/j.ymgme.2017.06.006","journal-title":"Mol Genet Metab"},{"key":"25_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ymgme.2016.10.006","volume":"120","author":"A Nowak","year":"2017","unstructured":"Nowak A, Mechtler TP, Desnick RJ, Kasper DC (2017) Plasma LysoGb3: a useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes. Mol Genet Metab 120:57\u201361. https:\/\/doi.org\/10.1016\/j.ymgme.2016.10.006","journal-title":"Mol Genet Metab"},{"key":"25_CR15","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s10157-017-1525-3","volume":"22","author":"H Sakuraba","year":"2018","unstructured":"Sakuraba H, Togawa T, Tsukimura T, Kato H (2018) Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy. Clin Exp Nephrol 22:843\u2013849. https:\/\/doi.org\/10.1007\/s10157-017-1525-3","journal-title":"Clin Exp Nephrol"},{"key":"25_CR16","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1073\/pnas.0712309105","volume":"105","author":"JM Aerts","year":"2008","unstructured":"Aerts JM, Groener JE, Kuiper S et al (2008) Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci 105:2812\u20132817. https:\/\/doi.org\/10.1073\/pnas.0712309105","journal-title":"Proc Natl Acad Sci"},{"key":"25_CR17","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1161\/HYPERTENSIONAHA.112.195685","volume":"60","author":"SM Rombach","year":"2012","unstructured":"Rombach SM, van den Bogaard B, de Groot E et al (2012) Vascular aspects of Fabry disease in relation to clinical manifestations and elevations in plasma Globotriaosylsphingosine. Hypertension 60:998\u20131005. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.112.195685","journal-title":"Hypertension"},{"key":"25_CR18","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ymgme.2013.11.012","volume":"111","author":"W-L Chuang","year":"2014","unstructured":"Chuang W-L, Pacheco J, Cooper S et al (2014) Lyso-sphingomyelin is elevated in dried blood spots of Niemann\u2013Pick B patients. Mol Genet Metab 111:209\u2013211. https:\/\/doi.org\/10.1016\/j.ymgme.2013.11.012","journal-title":"Mol Genet Metab"},{"key":"25_CR19","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s10545-017-0123-6","volume":"41","author":"MP Wasserstein","year":"2018","unstructured":"Wasserstein MP, Diaz GA, Lachmann RH et al (2018) Olipudase alfa for treatment of acid sphingomyelinase deficiency (ASMD): safety and efficacy in adults treated for 30 months. J Inherit Metab Dis 41:829\u2013838. https:\/\/doi.org\/10.1007\/s10545-017-0123-6","journal-title":"J Inherit Metab Dis"},{"key":"25_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2021.100780","volume":"28","author":"MS Breilyn","year":"2021","unstructured":"Breilyn MS, Zhang W, Yu C, Wasserstein MP (2021) Plasma lyso-sphingomyelin levels are positively associated with clinical severity in acid sphingomyelinase deficiency. Mol Gen Metab Rep 28:100780. https:\/\/doi.org\/10.1016\/j.ymgmr.2021.100780","journal-title":"Mol Gen Metab Rep"}],"container-title":["Methods in Molecular Biology","Clinical Applications of Mass Spectrometry in Biomolecular Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-2565-1_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T21:05:14Z","timestamp":1663707914000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-2565-1_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9781071625644","9781071625651"],"references-count":20,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-2565-1_25","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"type":"print","value":"1064-3745"},{"type":"electronic","value":"1940-6029"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"21 September 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}